Valuation: Geron Corporation

Market Cap 834M 730M 674M 630M 1.19B 78.85B 1.21B 8.11B 3.13B 38.9B 3.13B 3.06B 135B P/E 2026 *
-65x
P/E 2027 * 20x
Enterprise Value 813M 712M 657M 614M 1.16B 76.87B 1.18B 7.91B 3.05B 37.92B 3.05B 2.99B 132B EV / Sales 2026 *
3.48x
EV / Sales 2027 * 2x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-1.52%
1 week-2.99%
Current month+4.00%
1 month+4.00%
3 months-7.14%
6 months-5.11%
Current year-1.52%
1 week 1.28
Extreme 1.28
1.47
1 month 1.08
Extreme 1.08
1.47
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
20/05Free

Director

220,000 0.0343%
20/05Free

Director

220,000 0.0343%
20/05Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-1.52%-2.99%-12.75%-57.79% 834M
+0.13%-1.33%+63.86%+121.93% 55.78B
+6.76%+18.10%+91.66%+104.09% 55.66B
+3.33%+4.51%-11.68%-11.91% 23.84B
+1.32%+6.22%+5.28%+415.45% 22.7B
+0.97%+3.81%+31.23%-32.21% 16.12B
-0.89%+5.71%+24.30%+186.29% 13.64B
+9.96%+15.98%+157.65%+310.89% 14.8B
+2.85%+2.81%+75.32%+139.44% 12.16B
+6.17%+10.22%+163.15%+166.44% 11.85B
Average +2.91%+7.14%+58.80%+134.26% 22.74B
Weighted average by Cap. +3.30%+7.69%+63.82%+140.66%

Financials

2026 *2027 *
Net sales 234M 205M 189M 176M 332M 22.1B 340M 2.27B 878M 10.9B 878M 859M 37.85B 333M 292M 269M 251M 473M 31.5B 484M 3.24B 1.25B 15.54B 1.25B 1.22B 53.95B
Net income -13.95M -12.22M -11.28M -10.53M -19.83M -1.32B -20.28M -136M -52.4M -651M -52.4M -51.25M -2.26B 46.55M 40.76M 37.63M 35.14M 66.14M 4.4B 67.65M 453M 175M 2.17B 175M 171M 7.54B
Net Debt -20.97M -18.36M -16.95M -15.83M -29.8M -1.98B -30.47M -204M -78.74M -978M -78.75M -77.02M -3.4B -169M -148M -137M -128M -240M -15.98B -246M -1.64B -635M -7.88B -635M -621M -27.37B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
29/06/26 USD 1.300 -1.52% 14,561,547
26/06/26 USD 1.320 -3.65% 36,634,117
25/06/26 USD 1.370 -1.08% 9,546,037
24/06/26 USD 1.385 +2.59% 19,234,596
23/06/26 USD 1.350 +0.75% 13,103,262
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.300USD
Average target price
3.400USD
Spread / Average Target
+161.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock